Fang Ye
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Fang Ye has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Jingwen Zhou
Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine
2 shared publicationsJun Yu
The First Clinical Medical College of Nanjing University of Chinese Medicine, Nanjing
2 shared publicationsTianci Li
The First Clinical Medical College of Nanjing University of Chinese Medicine, Nanjing
2 shared publicationsXiaolong Zhang
Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine
2 shared publicationsZiyu Lu
School of Medicine & Holistic Integrative Medicine, Medical College of Nanjing University of Chinese Medicine
2 shared publicationsDongqing Yang Dongqing
Nanjing Univ Chinese Med, Sch Med & Holist Integrat Med, Dept Publ Hlth, Nanjing 210023, Peoples R China
1 shared publication
Latest Publications
- Open Access
- 19 June 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (25) , e49127
Association of pan-immune inflammation value and systemic immune inflammation index with mortality in MASLD: A cohort study from NHANES 1999 to 2018
Identifying prognostic risk factors in metabolic dysfunction-associated steatotic liver disease (MASLD) remains critical. This study investigates the association of the pan-immune inflammation value (PIV) and systemic immune inflammation index (SII) with mortality in the MASLD population. This cohort study used data from the National Health and Nutrition Examination Survey 1999 to 2018, associated with the National Death Index records, including 6252 patients with MASLD. Natural logarithms of PIV and SII (lnPIV, lnSII) were analyzed due to right-skewed distributions. Kaplan–Meier survival curves and multivariate Cox proportional hazards models were employed to assess the relationships between lnPIV, lnSII, all-cause and cardiovascular disease (CVD) mortality. Restricted cubic splines were applied to explore nonlinear trends, and segmented Cox regression was used to analyze threshold effects. Model performance was evaluated using the concordance index, time-dependent receiver operating characteristic curves, and calibration plots. Subgroup analyses were conducted to assess the robustness of the findings across different populations. Over a median follow-up of 9.17 years, 1154 all-cause deaths and 373 CVD-related deaths were recorded. Compared with individuals in the lowest quartile (Q1), those in the highest quartile (Q4) of lnPIV and lnSII had multivariable-adjusted hazard ratios of 1.36 (95% confidence interval [CI], 1.08–1.70) and 1.28 (95% CI, 1.02–1.61) for all-cause mortality, and 1.59 (95% CI, 1.00–2.52) and 1.76 (95% CI, 1.18–2.62) for CVD mortality, respectively. Nonlinear associations were observed between lnPIV, lnSII, and all-cause mortality, with thresholds identified at lnPIV = 6.015 and lnSII = 6.342. No significant associations were detected ( P > .05) below these thresholds, whereas a significant positive association was found above the thresholds ( P < .001). In contrast, a linear relationship was observed between lnPIV, lnSII, and CVD mortality. Time-dependent receiver operating characteristic curves and calibration plots demonstrated good model discrimination and calibration. No significant interactions were found across most subgroups ( P for interaction > .05). Elevated PIV and SII are associated with an increased risk of all-cause and CVD mortality in MASLD. A significantly higher hazard of all-cause mortality was observed when lnPIV and lnSII were above specific thresholds. They are potential tools that require external validation in patients with MASLD.
- 19 June 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (25) , e49127
Open AccessAssociation of pan-immune inflammation value and systemic immune inflammation index with mortality in MASLD: A cohort study from NHANES 1999 to 2018
Identifying prognostic risk factors in metabolic dysfunction-associated steatotic liver disease (MASLD) remains critical. This study investigates the association of the pan-immune inflammation value (PIV) and systemic immune inflammation index (SII) with mortality in the MASLD population. This cohort study used data from the National Health and Nutrition Examination Survey 1999 to 2018, associated with the National Death Index records, including 6252 patients with MASLD. Natural logarithms of PIV and SII (lnPIV, lnSII) were analyzed due to right-skewed distributions. Kaplan–Meier survival curves and multivariate Cox proportional hazards models were employed to assess the relationships between lnPIV, lnSII, all-cause and cardiovascular disease (CVD) mortality. Restricted cubic splines were applied to explore nonlinear trends, and segmented Cox regression was used to analyze threshold effects. Model performance was evaluated using the concordance index, time-dependent receiver operating characteristic curves, and calibration plots. Subgroup analyses were conducted to assess the robustness of the findings across different populations. Over a median follow-up of 9.17 years, 1154 all-cause deaths and 373 CVD-related deaths were recorded. Compared with individuals in the lowest quartile (Q1), those in the highest quartile (Q4) of lnPIV and lnSII had multivariable-adjusted hazard ratios of 1.36 (95% confidence interval [CI], 1.08–1.70) and 1.28 (95% CI, 1.02–1.61) for all-cause mortality, and 1.59 (95% CI, 1.00–2.52) and 1.76 (95% CI, 1.18–2.62) for CVD mortality, respectively. Nonlinear associations were observed between lnPIV, lnSII, and all-cause mortality, with thresholds identified at lnPIV = 6.015 and lnSII = 6.342. No significant associations were detected ( P > .05) below these thresholds, whereas a significant positive association was found above the thresholds ( P < .001). In contrast, a linear relationship was observed between lnPIV, lnSII, and CVD mortality. Time-dependent receiver operating characteristic curves and calibration plots demonstrated good model discrimination and calibration. No significant interactions were found across most subgroups ( P for interaction > .05). Elevated PIV and SII are associated with an increased risk of all-cause and CVD mortality in MASLD. A significantly higher hazard of all-cause mortality was observed when lnPIV and lnSII were above specific thresholds. They are potential tools that require external validation in patients with MASLD.
- 1 August 2022
- Vol. 42 (4) , 622-632
Identification of novel biomarkers and therapeutic target candidates for stasis-heat symptom pattern of acute intracerebral hemorrhage by quantitative plasma proteomics
OBJECTIVE: To explore the novel biomarkers and therapeutic target candidates related to the stasis-heat syndrome of acute intracerebral hemorrhage (AICH). METHODS: Applying an isobaric tagging for relative and absolute quantitation-(iTRAQ-) based quantitative proteomic approach, plasma samples from AICH patients with stasis-heat, and AICH patients with non-stasis-heat and healthy control subjects were collected and analyzed to distinguish differentially expressed proteins (DEPs) correlated to AICH with stasis-heat in this block design. The standard Western blot was applied to verify DEPs. Additionally, DEPs were analyzed via bioinformatic platforms and further approved via Ingenuity Pathway Analysis (IPA). RESULTS: A total of 26 DEPs were found among AICH with the stasis-heat, AICH with non-stasis-heat, and healthy control group. The seven DEPs compared with the non-stasis-heat group are closely related to the pathogenesis of stasis heat. These proteins showed three different protein expression patterns. The alpha-1-b glycoprotein (A1BG) and copper-protein (CP) were up-regulated in the stasis-heat group, but down-regulated in the non-stasis-heat group. Compared with the non-stasis-heat group, the expression abundance of actinin, alpha 1 (ACTN1), carbonic anhydrase I (CA1), peroxiredoxin 2 (PRDX2), and vinculin (VCL) is higher in the stasis-heat group, while the CD44 is the opposite. These differences reflect that stasis-heat syndrome has more severe inflammatory immune response, coagulation disorders and damage. Bioinformatics analysis revealed that a wide variety of cellular and metabolic processes and some signaling pathways were involved in the pathophysiology of AICH with stasis-heat. AICH with stasis-heat syndrome showed more severe inflammatory reactions, tissue damage, and coagulation disorders than non-stasis heat syndrome. CONCLUSIONS: There are differences in the protein expression patterns between the stasis-heat syndrome and non-stasis-heat syndrome. These differences reflect that stasis-heat syndrome has more severe damage. CD44, CP, ACTN1, CA1, VCL, PRDX2, and A1BG could be the potential biomarkers and therapeutic target candidates of the stasis-heat subtype. This study provides a reasonable explaination for Liangxue Tongyu decoction through anti-inflammatory and brain protection treatment. (c) 2022 JTCM. All rights reserved.
- 1 August 2022
- Vol. 42 (4) , 622-632
Identification of novel biomarkers and therapeutic target candidates for stasis-heat symptom pattern of acute intracerebral hemorrhage by quantitative plasma proteomics
OBJECTIVE: To explore the novel biomarkers and therapeutic target candidates related to the stasis-heat syndrome of acute intracerebral hemorrhage (AICH). METHODS: Applying an isobaric tagging for relative and absolute quantitation-(iTRAQ-) based quantitative proteomic approach, plasma samples from AICH patients with stasis-heat, and AICH patients with non-stasis-heat and healthy control subjects were collected and analyzed to distinguish differentially expressed proteins (DEPs) correlated to AICH with stasis-heat in this block design. The standard Western blot was applied to verify DEPs. Additionally, DEPs were analyzed via bioinformatic platforms and further approved via Ingenuity Pathway Analysis (IPA). RESULTS: A total of 26 DEPs were found among AICH with the stasis-heat, AICH with non-stasis-heat, and healthy control group. The seven DEPs compared with the non-stasis-heat group are closely related to the pathogenesis of stasis heat. These proteins showed three different protein expression patterns. The alpha-1-b glycoprotein (A1BG) and copper-protein (CP) were up-regulated in the stasis-heat group, but down-regulated in the non-stasis-heat group. Compared with the non-stasis-heat group, the expression abundance of actinin, alpha 1 (ACTN1), carbonic anhydrase I (CA1), peroxiredoxin 2 (PRDX2), and vinculin (VCL) is higher in the stasis-heat group, while the CD44 is the opposite. These differences reflect that stasis-heat syndrome has more severe inflammatory immune response, coagulation disorders and damage. Bioinformatics analysis revealed that a wide variety of cellular and metabolic processes and some signaling pathways were involved in the pathophysiology of AICH with stasis-heat. AICH with stasis-heat syndrome showed more severe inflammatory reactions, tissue damage, and coagulation disorders than non-stasis heat syndrome. CONCLUSIONS: There are differences in the protein expression patterns between the stasis-heat syndrome and non-stasis-heat syndrome. These differences reflect that stasis-heat syndrome has more severe damage. CD44, CP, ACTN1, CA1, VCL, PRDX2, and A1BG could be the potential biomarkers and therapeutic target candidates of the stasis-heat subtype. This study provides a reasonable explaination for Liangxue Tongyu decoction through anti-inflammatory and brain protection treatment. (c) 2022 JTCM. All rights reserved.
- Open Access
- 26 March 2021
- Published by Wolters Kluwer Health in Medicine
- Vol. 100 (12) , e24884
The efficacy of novel metabolic targeted agents and natural plant drugs for nonalcoholic fatty liver disease treatment
Background: Nonalcoholic fatty liver disease (NAFLD) is a highly prevalent chronic liver disease characterized by excess accumulation of fat in hepatocytes. Because no drug has been approved for NAFLD treatment, this work analyzed the effects of agents resulting from 2 research hotspots, metabolic target agents, and natural plant drugs, on NAFLD with network meta-analysis. Methods: Public databases were searched through August 14, 2020. Randomized controlled trials that compared obeticholic acid, elafibranor, cenicriviroc, selonsertib, curcumin, silymarin, and resveratrol to placebo were included. Liver pathology improvement, hepatic biochemical indicators, and lipid metabolism indicators were analyzed. Results: Thirty-five studies were included in the meta-analysis. Obeticholic acid was found to significantly increase the frequency of liver biopsy improvement compared to placebo (OR: 2.10; 95% CI: 1.60, 2.77). The ranking results among the hepatic biochemical indicators showed that obeticholic acid (94.9%) and elafibranor (86.3%) have a relative advantage in reducing alanine aminotransferase (ALT) levels, and obeticholic acid also had an advantage (95.4%) in reducing aspartate aminotransferase (AST) levels. Considering lipid metabolic indicators, elafibranor (expSMD: 0.01; 95% CI: 0.00, 0.05; SUCRA: 100%), and obeticholic acid (expSMD: 0.48; 95% CI: 0.28,0.84; SUCRA: 75.6%) significantly reduced triglyceride (TG) levels compared with placebo; moreover, obeticholic acid, but not elafibranor, caused a serious increase in total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) levels and a decrease in high-density lipoprotein cholesterol (HDL-C) levels. Conclusions: Novel metabolic targeted agents generally have better effects than natural plant drugs, especially obeticholic acid, and elafibranor. However, obeticholic acid showed serious adverse effects such as increasing LDL-C levels and decreasing HDL-C levels. Curcumin showed potential advantages for NAFLD but lacked statistical significance.
- 26 March 2021
- Published by Wolters Kluwer Health in Medicine
- Vol. 100 (12) , e24884
Open AccessThe efficacy of novel metabolic targeted agents and natural plant drugs for nonalcoholic fatty liver disease treatment
Background: Nonalcoholic fatty liver disease (NAFLD) is a highly prevalent chronic liver disease characterized by excess accumulation of fat in hepatocytes. Because no drug has been approved for NAFLD treatment, this work analyzed the effects of agents resulting from 2 research hotspots, metabolic target agents, and natural plant drugs, on NAFLD with network meta-analysis. Methods: Public databases were searched through August 14, 2020. Randomized controlled trials that compared obeticholic acid, elafibranor, cenicriviroc, selonsertib, curcumin, silymarin, and resveratrol to placebo were included. Liver pathology improvement, hepatic biochemical indicators, and lipid metabolism indicators were analyzed. Results: Thirty-five studies were included in the meta-analysis. Obeticholic acid was found to significantly increase the frequency of liver biopsy improvement compared to placebo (OR: 2.10; 95% CI: 1.60, 2.77). The ranking results among the hepatic biochemical indicators showed that obeticholic acid (94.9%) and elafibranor (86.3%) have a relative advantage in reducing alanine aminotransferase (ALT) levels, and obeticholic acid also had an advantage (95.4%) in reducing aspartate aminotransferase (AST) levels. Considering lipid metabolic indicators, elafibranor (expSMD: 0.01; 95% CI: 0.00, 0.05; SUCRA: 100%), and obeticholic acid (expSMD: 0.48; 95% CI: 0.28,0.84; SUCRA: 75.6%) significantly reduced triglyceride (TG) levels compared with placebo; moreover, obeticholic acid, but not elafibranor, caused a serious increase in total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) levels and a decrease in high-density lipoprotein cholesterol (HDL-C) levels. Conclusions: Novel metabolic targeted agents generally have better effects than natural plant drugs, especially obeticholic acid, and elafibranor. However, obeticholic acid showed serious adverse effects such as increasing LDL-C levels and decreasing HDL-C levels. Curcumin showed potential advantages for NAFLD but lacked statistical significance.
- Open Access
- 9 February 2021
- Published by International Scientific Information, Inc. in Medical Science Monitor
- Vol. 27, e929438-e929438-12
Zi Qi Decoction Alleviates Liver Fibrosis by Inhibiting the Toll-Like Receptor 4 (TLR4)-Related Nuclear Factor kappa b (NF-κB) and Mitogen-Activated Protein Kinase (MAPK) Signaling Pathways
Zi Qi Decoction Alleviates Liver Fibrosis by Inhibiting the Toll-Like Receptor 4 (TLR4)-Related Nuclear Factor kappa b (NF-κB) and Mitogen-Activated Protein Kinase (MAPK) Signaling Pathways - Article abstract #929438
- 9 February 2021
- Published by International Scientific Information, Inc. in Medical Science Monitor
- Vol. 27, e929438-e929438-12
Open AccessZi Qi Decoction Alleviates Liver Fibrosis by Inhibiting the Toll-Like Receptor 4 (TLR4)-Related Nuclear Factor kappa b (NF-κB) and Mitogen-Activated Protein Kinase (MAPK) Signaling Pathways
Zi Qi Decoction Alleviates Liver Fibrosis by Inhibiting the Toll-Like Receptor 4 (TLR4)-Related Nuclear Factor kappa b (NF-κB) and Mitogen-Activated Protein Kinase (MAPK) Signaling Pathways - Article abstract #929438